Cantor Fitzgerald Sticks to Their Hold Rating for Alnylam Pharma (ALNY)

Cantor Fitzgerald analyst Olivia Brayer maintained a Hold rating on Alnylam Pharma on February 12 and set a price target of $400.00. The company’s shares closed last Friday at $308.48.

President's Day Sale - 70% Off

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Brayer covers the Healthcare sector, focusing on stocks such as Vanda, CytomX Therapeutics, and Insmed. According to TipRanks, Brayer has an average return of 6.7% and a 46.15% success rate on recommended stocks.

In addition to Cantor Fitzgerald, Alnylam Pharma also received a Hold from TipRanks – OpenAI’s OpenAI Biotechnology in a report issued yesterday. However, on the same day, TipRanks – Google upgraded Alnylam Pharma (NASDAQ: ALNY) to a Buy.

Based on Alnylam Pharma’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.1 billion and a net profit of $186.42 million. In comparison, last year the company earned a revenue of $593.17 million and had a GAAP net loss of $83.76 million

Based on the recent corporate insider activity of 98 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALNY in relation to earlier this year. Last month, Fitzgerald Kevin Joseph, the CSO & EVP, Head of Research of ALNY sold 1,510.00 shares for a total of $547,927.38.